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Introduction. In sub-Saharan Africa (SSA), there is a significant burden of ischemic stroke (IS) and hemorrhagic stroke (HS),
although data on risk factors for each type are sparse. In this systematic review we attempt to characterize the risk factors.Methods.
We systematically reviewed (PubMed, EMBASE, WHOLIS, Google Scholar, Wiley online, and the Cochrane Central Register of
Controlled Trials (CENTRAL)) case-control studies and case series from 1980 to 2016 that reported risk factors for IS and/or HS
in SSA. For each risk factor we calculated random-effects pooled odds ratios (ORs) for case-control studies and pooled prevalence
estimates for case series. Results. We identified 12 studies, including 4,387 stroke patients. Pooled analysis showed that patients who
had diabetes (OR = 2.39; 95% CI: 1.14–5.03) and HIV (OR = 2.46 (95% CI: 1.59–3.81) were at a significantly greater risk of suffering
from all stroke types.There were insufficient data to examine these factors by stroke type. Among case series, the pooled prevalence
of hypertension was higher for HS than for IS (73.5% versus 62.8%), while diabetes mellitus (DM) and atrial fibrillation (AF) were
more prevalent among IS compared to HS (15.9% versus 10.6% and 9.6% versus 2.3%, respectively). Conclusions.There remain too
few data from SSA to reliably estimate the effect of various factors on the risk of IS and HS. Furthermore, the vast majority of cases
were identified in hospital and so are unlikely to be representative of the totality of stroke cases in the community.
1. Background
Worldwide, stroke is a leading cause of death and of chronic
disability [1]. It is estimated that 15 million people suffer a
stroke annually; of these, fivemillion die and another fivemil-
lion are left permanently disabled, placing a burden on family
and community [2]. Approximately 85% of deaths are in low
andmiddle income countries [3]. In SSA stroke represents an
important part of the chronic disease burden [4], but there are
relatively few data on risk factors.
Stroke is a heterogeneous disease comprising subarach-
noid hemorrhage, intraparenchymal hemorrhage, and IS,
each of which has a very different pathophysiology [5]. HS is
thought to account for 15–20% of strokes worldwide, while
IS accounts for 80–85%, although there are geographic
variations [6]. In SSA, several nonmodifiable risk factors for
stroke, such as age, gender, race, ethnicity, and heredity have
been identified [7–9]. Potentially modifiable risk factors in-
clude hypertension, AF, hyperlipidemia, DM, cigarette smok-
ing, physical inactivity, and transient ischemic attack (TIA)
[7, 8]. Although the risk factors for HS and IS appear to vary
considerably between countries [10], hypertension remains
the most important stroke risk factor globally [11]. The
INTERSTROKE study demonstrated the commonality of the
main risk factors for stroke in SSA: hypertension (37%), alco-
hol intake (11%), physical inactivity (12%), andDM(12%) [12].
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For example in Uganda, Ethiopia, and Zambia, some cross-
sectional studies have shown a prevalence of stroke risk fac-
tors typical of countries in sub-Saharan Africa [13–17]. Simi-
lar trends were found in Sierra Leone, Tanzania, Kenya, Zim-
babwe, Ethiopia, and Nigeria where hypertension was estab-
lished to be the most common stroke risk factor, followed by
diabetes mellitus, smoking, and alcohol intake [8, 12, 18–22].
However, there are relatively few data from SSA that
examine risk factors for stroke and in particular for HS and
IS separately. Here, we systematically review the available
data, thereby summarizing what is known and highlighting
gaps in knowledge on a continent that is undergoing rapid
epidemiological transition.
2. Methods
2.1. Eligibility Criteria. Articles which were included in the
review met the following inclusion criteria: (1) cohort, case-
control, cross-sectional, or randomized control trial study
design; (2) studies reporting risk factors for HS and IS with
effectmeasures and 95% confidence intervals and usedmulti-
variable data analysis; (3) studies with data collected among
adult patients aged 18 years and older; (4) studies con-
ducted in SSA countries; (5) studies whose participants were
clinically diagnosed with stroke as defined by the WHO
criteria; (6) where stroke subtype was classified, it was by
computer tomography (CT), magnetic resonance (MR), and
brain imaging or necropsy; (7) articles published in English
from 1980 to 2016; (8) studies from both community and
hospital-based settings of first-ever aswell as recurrent stroke.
The exclusion criteria were as follows: (1) the original
article did not have relevant information on risk factors for
HS and IS; (2) duplicate report; (3) results presented only as
abstracts; (4) population not living in SSA; (5) studies includ-
ing children; (6) studies with unclear or no available informa-
tion on risk factors in all stroke or individual stroke types or
data inconsistencies. Full text/papers were sought for all stud-
ies appearing to meet the inclusion criteria based on screen-
ing of the abstract, and a final selectionwasmade by two inde-
pendent reviewers. Figure 1 shows a flow chart which was
produced to facilitate transparency of the process.
2.2. Search Strategy. Standardised and well described meth-
ods were used in this systematic review [23]. Briefly, a search
strategy was developed after identification of the relevant
Medical Subject Headings (MESH), keywords, and their syn-
onyms. The searches were conducted in six main databases:
PubMed, EMBASE, WHOLIS, Google Scholar, Wiley online,
and CENTRAL.
The search strategy for PubMed: the key words which we
used in our search included terms describing stroke, terms
describing age, terms describing the SSA countries, and terms
describing risk factors as shown in the search strategy as
follows:
(1) (Stroke[Title] OR “Ischemic stroke”[Title] OR
“Ischaemic stroke”[Title] OR “haemorrhagic
stroke”[Title]OR “hemorrhagic stroke”OR “Cerebral
Vascular accident” OR CVA)
(2) (Adults OR “18 years or older”)
(3) (“Sub-Saharan Africa”[Text Word] OR “Africa
South of the Sahara” OR Angola[Text Word] OR
Benin[Text Word] OR Botswana[Text Word] OR
Burkina Faso[Text Word] OR Burundi[Text word]
OR Cameroon[Text Word] OR “Cape Verde” OR
“Central African Republic” OR Chad[TextWord] OR
Comoros[Text Word] OR Congo (Democratic
Republic) OR Congo (DRC- Kinshasa)[Text
Word] OR “Coˆte d’Ivoire” OR Djibouti[Text
Word] OR Eritrea[Text word] OR “Equatorial
Guinea” OR “Congo Brazzaville” OR Ethiopia[Text
Word] OR Gabon[Text word] OR Gambia[Text
word] OR Ghana[Text Word] OR Guinea[Text
Word] OR Guinea-Bissau[Text word] OR “Ivory
Coast”[Text Word] OR Kenya[Text Word] OR
Lesotho[Text Word] OR Liberia[Text word] OR
Madagascar[Text Word] OR Malawi[Text Word]
OR Mauritius[Text Word] OR Mozambique[Text
Word] OR Namibia[Text Word] OR Niger[Text
Word] OR Nigeria[Text Word] OR Re´union[Text
word] OR Rwanda[Text Word] OR “Sao Tome and
Principe”[Text word] OR Senegal[Text Word] OR
Seychelles[Text word] OR “Sierra Leone”[TextWord]
OR Somalia[Text word] OR “South Africa”[Text
Word] OR Sudan[Text word] OR Swaziland[Text
Word] OR Tanzania[Text Word] OR Togo[Text
Word] OR Uganda[Text Word] OR Zambia[Text
Word] OR Zimbabwe[text word])
(4) (Hypertension OR “High blood pressure” [Text
Word] OR Diabetes[Text Word] OR “Diabetes melli-
tus” OR Smoking OR Alcohol OR Obesity OR “Atrial
fibrillation” [Text Word])
(5) #1 AND #2AND#3AND#4 Limits: English language
The search yielded 617 abstracts. All abstracts were screened,
and we assessed full papers of all abstracts meeting the
inclusion criteria. We reviewed all relevant articles in English
from 1980 to 2016. Stroke was defined as “rapidly developing
clinical signs of focal, or at times, global disturbance of
cerebral function, lasting more than 24 hours or leading to
death with no apparent cause other than vascular origin” [2]
as per the WHO criteria.
An additional search was conducted in reference lists of
relevant studies, journals, theses, and conference proceedings
to identify publications that could have been omitted in the
database searches.
2.3. Study Selection. Two review authors (GN, AK) inde-
pendently screened titles and abstracts of records obtained
from the electronic searches and excluded those that were
obviously irrelevant. We obtained the full text of the remain-
ing studies and selected those for inclusion according to the
above criteria. If any methodological question raised doubts
about whether the study met the inclusion criteria, we con-
tacted the study authors for clarification. If there was dis-
agreement regarding the selection of studies, we attempted to
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Figure 1: PRISMA flow diagram for the systematic review of risk factors for hemorrhagic and ischemic stroke in sub-Saharan Africa.
Footnotes. The flow diagram template was adopted from the PRISMA statement [23].
reach a consensus. We recorded reasons for exclusion (Fig-
ure 1).
2.4. Data Extraction and Quality Assessment. Data were ex-
tracted from identified studies using a structured form by the
primary reviewer (GN). A second reviewer (AK) indepen-
dently checked the data extraction forms for accuracy and
detail. We extracted the following information: (1) general
information such as author, date of publication, and country;
(2) study duration and sample size; (3) total number of partic-
ipants, gender, and stroke type; (4) risk factors for stroke such
as hypertension, DM, smoking, alcohol use, dyslipidaemia,
HIV infection, and hypercholesterolemia. Two investigators
(GN and OK) independently evaluated the methodological
quality and risk of bias of eligible studies by using the
Newcastle-Ottawa scale [28] and the Preferred Reporting
Items for Systematic Reviews and Meta- Analyses (PRISMA)
guidelines [23]. The studies were assessed on selection bias,
definition of cases and controls, representativeness of the
cases and controls, comparability of cases and controls, and
ascertainment of exposure. Disagreements between two au-
thors were resolved by discussions and if this was not possi-
ble, another senior investigator (RN) was consulted and par-
ticipated in the discussions until consensus was reached.
2.5. Statistical Analyses. For each risk factor, where data were
available from more than one study, we performed meta-
analyses.We calculated study-specific odds ratios and pooled
prevalence in HS and IS patients with 95% confidence inter-
vals (CIs) separately. We used a random-effects model for
meta-analyses since there was evidence of heterogeneity [29].
Heterogeneity among studies was assessed visually with a
forest plot and quantitatively with the 𝐼2 index.The threshold
of heterogeneity was set at 𝐼2 ≥ 50%. All meta-analyses were
performed with STATA version 12.0 and REVMAN. Statisti-
cal significance was set at 𝑝 ≤ 0.05. To assess whether pooled
prevalence and ORs for each risk factor comparison differed
between HS and IS, we assessed between-group hetero-
geneity, using the within-group pooled estimates and their
standard errors.
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3. Results
The literature search identified 617 publications from
PubMed (330), EMBASE (1), WHOLIS (61), CENTRAL (18),
Google scholar (36), and Wiley online (171). Additional 6
studies were included from reference lists of relevant pub-
lications. Five hundred and sixty-two (562) studies remained
after removing 61 duplicates. After screening the titles and
abstracts for relevance, 532 studies were excluded (19 were
systematic reviews, 40 were among participants < 18 years,
and 473 studies did not report data either on ischemic or
hemorrhagic stroke risk factors separately) giving a total of 30
full texts that were assessed. After applying quality criteria,
another 18 were excluded which did not have enough infor-
mation on risk factors for hemorrhagic and ischemic stroke.
A total of 12 studies were finally retained for the review. A
summary of the selection process is shown in Figure 1.
3.1. Characteristics of the Case-Control Studies Included in
the Meta-Analysis. There were five case-control studies [8,
12, 30–32] included in the final meta-analysis. Three [30–32]
were single centre studies, while two [8, 12] were multicentre
studies. All were matched case-control studies and reported
information on more than one risk factor. The sample size
ranged from 163 to 646.The total sample size fromall retained
studies was 2,384. Four studies used computed tomography
(CT) scan for case ascertainment to confirm diagnosis while
one study [30] used clinical assessment.Three studies report-
ed information on the association between hypertension and
stroke: four on diabetes and stroke, four on alcohol use and
stroke, four on smoking and stroke, three on HIV infection
and stroke, and two on hypercholesterolemia and stroke.
Of the 5 studies, only one reported risk factors for HS and
IS separately. Table 1 summarizes the characteristics of the
included studies.
3.2. Characteristics of Case Series Included in the Quantitative
Synthesis. Seven studies [15–17, 24–27] were included in the
final synthesis. All were conducted in hospital-based settings.
The total sample size from all retained studies was 2003 with
the mean of 286 (SD 195) and the median of 250 (IQR 139,
432). The pooled mean age for HS was 53.84 (SD 2.42) while
the mean age for IS was 58.7 (SD 6.1). All seven studies used
CT scan for case ascertainment to confirm diagnosis, two
studies [26, 27] used both MRI and CT scan, while only one
study [24] used both CT scan and necropsy. All seven studies
reported risk factor data for HS and IS, but only one [17] also
reported other risk factor data on TIA and other stroke types
(Table 2).
3.3. Analysis of Case-Control Studies. Among five case-
control studies [8, 12, 30–32], we examined six risk factors for
stroke: hypertension, DM, alcohol use, HIV infection, smok-
ing, and hypercholesterolemia. These were risk factors with
data available from more than one study. These five showed
moderate to substantial heterogeneity between studies; hence
random-effects models rather than fixed-effects were used to
pool the ORs. A meta-analysis of risk factors for all stroke
is summarized in Figure 2. Only one study [8] reported data
on risk factors for HS and IS separately and so we could
not perform ameta-analysis [33].The risk factor associations
with stroke are summarized in Table 3.
3.4. DiabetesMellitus. Four studies [8, 12, 31, 32] reported rel-
evant data onDM and its association with all stroke. Of these,
only one study [8] assessed the associated risk of diabeteswith
HS and IS. Using a random-effects model, the pooled ORwas
2.39 (95% CI: 1.14–5.03) for all strokes. There was substantial
heterogeneity among studies (I2 = 68.0). One study [8] re-
ported that DM was associated with an increased risk of IS
(OR = 1.60; 99% CI: 1.29–1.99) compared to HS.
3.5. Alcohol Use. The effect of alcohol use on stroke risk was
reported in four studies [8, 12, 31, 32]. Only one study [8]
reported the risk on HS and IS.There was substantial hetero-
geneity among studies (I2 = 74.0%) in study effect size esti-
mates. Using a random-effects model, the pooled OR was
1.26 (95% CI: 0.68–2.35). However one study [8] reported
that history of alcohol intake of 1–30 drinks per month was
associated with a reduced risk of IS (OR = 0.79; 99% CI:
0.63–1.00), while, for intracerebralHS, the risk increasedwith
alcohol intake (OR 2.01; 99% CI: 1.35–2.99).
3.6. Smoking. Four studies [8, 12, 31, 32] reported relevant
data on smoking and its effect on all stroke risk and again,
only one [8] reported the risk with HS and IS. In the analysis
both current and ever smoking were considered. There was
considerable heterogeneity among studies (I2 = 68.0). Using
a random-effects model the pooled OR was 1.02 (95% CI:
0.59–1.79). However one study [8] reported that smoking
was associated with an greater risk of IS (OR 2.33, 99% CI,
1.91–2.81) compared to HS (OR 1.45, 99% CI, 1.07–1.96).
3.7. HIV Infection. Three studies [12, 30, 32] reported relevant
data on HIV infection and its association with all stroke.
There was moderate heterogeneity among studies (I2 =
31.0%). The pooled OR was 2.46 (95% CI: 1.59–3.81).
3.8. Hypertension. The risk of stroke with hypertension was
reported in three case-control studies [8, 12, 32]; only one
study [8] reported data on the risk with HS and IS. There
was considerable heterogeneity among studies (𝐼2 = 89.0%)
in study effect size estimates and random-effects pooled OR
was 1.66 (95%CI: 0.78–3.55). One study [8] reported that self-
reported hypertension or high blood pressure > 160/90mm
Hg was the strongest risk factor for all stroke (OR = 3.80;
99% CI: 3.33–4.54), but more so for HS (OR = 9.18; 99% CI:
6.80–12.39) than for IS (OR = 3.14; 99% CI: 2.67–3.71).
3.9. Hypercholesterolemia. Two studies [12, 32] assessed the
risk of hypercholesterolemia and all stroke. Using a fixed-
effects model, the pooled OR was 1.18; 95% CI: 0.85–1.63.
There was no heterogeneity among studies (I2 = 0.0%).
3.10. Analysis of the Case Series. Because there were insuffi-
cient data from case-control studies to examine risk factors
Journal of Tropical Medicine 5
Ta
bl
e
1:
Ch
ar
ac
te
ris
tic
so
fc
as
e-
co
nt
ro
ls
tu
di
es
in
clu
de
d
in
th
es
ys
te
m
at
ic
re
vi
ew
.
Au
th
or
,y
ea
r
Se
tti
ng
St
ud
y
de
sig
n
St
ro
ke
ty
pe
(I
S/
H
S)
Ca
se
s
(𝑛
)
C
on
tro
ls
(𝑛
)
G
en
de
r
H
yp
er
te
ns
io
n
D
M
A
lc
oh
ol
us
e
Cu
rr
en
t
sm
ok
in
g
H
IV
se
ro
-
po
sit
iv
ity
H
yp
er
ch
ol
es
te
ro
le
m
ia
As
ik
ie
ta
l.
(2
01
5)
Si
ng
le
ce
nt
er
-S
ou
th
w
es
te
rn
U
ga
nd
a
Ca
se
co
nt
ro
l
N
ot
re
po
rt
ed
31
13
2
+
-
-
-
-
+
-
O
’D
on
ne
ll
et
al
.(
20
10
)
M
ul
tic
en
te
r-
U
ga
nd
a,
M
oz
am
bi
qu
e,
So
ut
h
A
fr
ic
a,
Su
da
n,
N
ig
er
ia
Ca
se
co
nt
ro
l
21
4/
10
9
32
3
32
3
+
+
+
+
+
-
-
O
w
ol
ab
ie
ta
l.
(2
01
3)
Si
ng
le
ce
nt
er
-U
ni
ve
rs
ity
C
ol
le
ge
H
os
pi
ta
l,
Ib
ad
an
,N
ig
er
ia
Ca
se
co
nt
ro
l
60
/3
0
13
5
117
+
-
+
+
+
-
-
Be
nj
am
in
et
al
.(
20
15
)
Si
ng
le
ce
nt
er
-Q
ue
en
El
iz
ab
et
h
C
en
tr
al
H
os
pi
ta
l,
Bl
an
ty
re
di
st
ric
t,
M
al
aw
i
Ca
se
co
nt
ro
l
N
ot
re
po
rt
ed
22
2
50
3
+
+
+
+
+
+
+
W
al
ke
re
ta
l.
(2
01
3)
M
ul
tic
en
te
r-
ru
ra
lH
ai
di
st
ric
ti
n
no
rt
he
rn
Ta
nz
an
ia
,
an
d
ur
ba
n
D
ar
-e
s-
Sa
la
am
-
Ta
nz
an
ia
Ca
se
co
nt
ro
l
66
/14
20
0
39
8
+
+
+
+
+
+
+
+
=
in
fo
rm
at
io
n
av
ai
la
bl
e;
-=
in
fo
rm
at
io
n
no
ta
va
ila
bl
e.
6 Journal of Tropical Medicine
Ta
bl
e
2:
Ch
ar
ac
te
ris
tic
so
fc
as
es
er
ie
si
nc
lu
de
d
in
th
es
ys
te
m
at
ic
re
vi
ew
.
Au
th
or
,y
ea
r
C
ou
nt
ry
Pa
tie
nt
re
cr
ui
tm
en
ta
nd
se
tti
ng
Ca
se
de
fin
iti
on
Ca
se
as
ce
rt
ai
nm
en
t
St
ro
ke
ty
pe
M
ea
n
ag
e
(y
ea
rs
)
Sa
m
pl
es
iz
e
IS
/H
S
(%
)
Ri
sk
fa
ct
or
sr
ep
or
te
d
M
ay
ow
ae
ta
l.,
20
13
N
ig
er
ia
H
os
pi
ta
lb
as
ed
co
ns
ec
ut
iv
ea
du
lt
str
ok
e
pa
tie
nt
s
N
R
CT
sc
an
an
d/
or
M
RI
Is
ch
em
ic
an
d
he
m
or
rh
ag
ic
60
.8
28
2
61
.7
/3
3.
3
A
ge
,s
ex
,h
yp
er
te
ns
io
n,
w
ai
st
hi
p
ra
tio
,d
ia
be
te
s,
hy
pe
rc
ho
le
ste
ro
le
m
ia
,
al
co
ho
lu
se
,s
m
ok
in
g,
ph
ys
ic
al
in
ac
tiv
ity
,b
od
y
m
as
si
nd
ex
A
lb
er
tin
o
et
al
.,
20
10
M
oz
am
bi
qu
e
H
os
pi
ta
lb
as
ed
ad
ul
t
st
ro
ke
ad
m
iss
io
ns
W
H
O
CT
sc
an
an
d
ne
cr
op
sy
Is
ch
em
ic
an
d
he
m
or
rh
ag
ic
59
.1
65
1
42
.0
/3
6.
1
A
ge
,s
ex
,r
ac
e,
hy
pe
rt
en
sio
n,
di
ab
et
es
,
dy
sli
pi
da
em
ia
,A
F
Se
nn
ay
et
al
.,
20
16
Et
hi
op
ia
H
os
pi
ta
lb
as
ed
ad
ul
t
str
ok
ep
at
ie
nt
s
N
R
CT
sc
an
an
d
ne
ur
ol
og
ic
al
ev
al
ua
tio
n
Is
ch
em
ic
he
m
or
rh
ag
ic
,
TI
A
an
d
ot
he
r
62
.8
14
2
55
.6
/3
2.
4
A
ge
,s
ex
,h
yp
er
te
ns
io
n,
di
ab
et
es
,a
dd
re
ss
Sa
gu
ie
ta
l.,
20
05
Se
ne
ga
l
H
os
pi
ta
lb
as
ed
ad
ul
t
st
ro
ke
ad
m
iss
io
ns
W
H
O
CT
sc
an
Is
ch
em
ic
an
d
he
m
or
rh
ag
ic
60
.4
10
7
70
.0
/3
0.
0
A
ge
,h
yp
er
te
ns
io
n,
di
ab
et
es
,s
m
ok
in
g,
hy
pe
rc
ho
le
ste
ro
le
m
ia
,
A
F
C
on
no
re
ta
l.,
20
07
So
ut
h
A
fr
ic
a
H
os
pi
ta
lb
as
ed
co
ns
ec
ut
iv
ea
du
lt
str
ok
e
pa
tie
nt
s
W
H
O
CT
sc
an
or
M
RI
Is
ch
em
ic
an
d
he
m
or
rh
ag
ic
53
43
2
58
.0
/4
2.
0
A
ge
,m
al
es
ex
,
hy
pe
rt
en
sio
n,
di
ab
et
es
,
hy
pe
rc
ho
le
ste
ro
le
m
ia
,
al
co
ho
lu
se
,s
m
ok
in
g,
A
F,
TI
A
N
ak
ib
uu
ka
et
al
.,
20
12
U
ga
nd
a
H
os
pi
ta
lb
as
ed
co
ns
ec
ut
iv
ea
du
lt
str
ok
e
pa
tie
nt
s
N
R
CT
sc
an
Is
ch
em
ic
an
d
he
m
or
rh
ag
ic
62
.2
13
9
77
.6
/2
2.
4
A
ge
,s
ex
,h
yp
er
te
ns
io
n,
di
ab
et
es
,s
m
ok
in
g,
al
co
ho
lu
se
,p
hy
sic
al
in
ac
tiv
ity
M
as
ha
rip
et
al
.,
20
12
Za
m
bi
a
H
os
pi
ta
lb
as
ed
ad
ul
t
str
ok
ep
at
ie
nt
s
W
H
O
W
H
O
CT
sc
an
Is
ch
em
ic
an
d
he
m
or
rh
ag
ic
55
25
0
65
/3
5
A
ge
,m
al
es
ex
,
hy
pe
rt
en
sio
n,
di
ab
et
es
,
sm
ok
in
g,
al
co
ho
lu
se
,
H
IV
in
fe
ct
io
n,
pr
ev
io
us
str
ok
e,
A
F
N
R
=
no
tr
ep
or
te
d.
Journal of Tropical Medicine 7
Cases Controls Odds Ratio Odds RatioStudy or Subgroup
Events Events M-H, Random, 95% CI M-H, Random, 95% CI
1.2.1 Diabetes
Benjamin et al,2015 19 503 5.1% 4.19 [1.96, 8.95]
Owolabi et al,2013 29 117 5.9% 1.25 [0.67, 2.34]
Walker et al,2013 15 200 
222
11
11
398 4.8% 2.85 [1.28, 6.33]
Subtotal (95% CI) 557 1018 15.8% 2.39 [1.14, 5.03]
Total events 63 43
Test for overall eﬀect: Z = 2.30 (P = 0.02)
1.2.2 Alcohol
Benjamin et al,2015 34 222 92 503 7.3% 0.81 [0.53, 1.24]
Owolabi et al,2013 33 135 13 117 5.5% 2.59 [1.29, 5.20]
Walker et al,2013 24 200 43 398 6.6% 1.13 [0.66, 1.91]
Subtotal (95% CI) 557 1018 19.4% 1.26 [0.68, 2.35]
Total events 91 148
Test for overall eﬀect: Z = 0.74 (P = 0.46)
1.2.3 Smoking
Benjamin et al,2015 41 222 63 503 7.3% 1.58 [1.03, 2.43]
Owolabi et al,2013 11 135 11 117 4.4% 0.85 [0.36, 2.05]
Walker et al,2013 31 200 80 398 7.2% 0.73 [0.46, 1.15]
Subtotal (95% CI) 557 1018 18.9% 1.02 [0.59, 1.79]
Total events 83 154
Test for overall eﬀect: Z = 0.08 (P = 0.93)
1.2.4 HIV
Asiki et al,2015 5 31 8 132 3.0% 2.98 [0.90, 9.84]
Benjamin et al,2015 69 222 95 503 7.8% 1.94 [1.35, 2.78]
Walker et al,2013 25 200 15 398 5.7% 3.65 [1.88, 7.09]
Subtotal (95% CI) 453 1033 16.5% 2.46 [1.59, 3.81]
Total events 99 118
Test for overall eﬀect: Z = 4.04 (P < 0.0001)
1.2.5 Hypertension
Benjamin et al,2015 165 222 273 503 7.9% 2.44 [1.72, 3.46]
Walker et al,2013 143 200 275 398 7.7% 1.12 [0.77, 1.63]
Subtotal (95% CI) 422 901 15.7% 1.66 [0.78, 3.55]
Total events 308 548
Test for overall eﬀect: Z = 1.30 (P = 0.19)
1.2.6 Hypercholesterolemia
Benjamin et al,2015 18 222 28 503 6.0% 1.50 [0.81, 2.77]
Walker et al,2013 54 200 102 398 7.7% 1.07 [0.73, 1.58]
Subtotal (95% CI) 422 901 13.7% 1.18 [0.85, 1.63]
Total events 72 130
Test for overall eﬀect: Z = 0.99 (P = 0.32)
Total (95% CI) 2968 5889 100.0% 1.57 [1.22, 2.02]
Total events 716 1141
Test for overall eﬀect: Z = 3.50 (P = 0.0005) 0.002 1 10
Test for subgroup diﬀerences: Reduced risk
21135
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Figure 2: A meta-analysis of risk factors for all stroke in sub-Saharan Africa.
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Table 3: Risk factors for all stroke expressed as odds ratios with 95% CI values.
Risk factor 𝑛 Pooled OR (95% CI) 𝐼2 (%)
Hypertension 3 1.66 (0.78-3.55) 88.7
DM 4 2.39 (1.14–5.03) 68.2
Alcohol use 4 1.26 (0.68–2.35) 74.2
Smoking 4 1.02 (0.59–1.79) 67.6
HIV infection 3 2.46 (1.59–3.81) 30.9
Hypercholesterolemia 2 1.18 (0.85–1.63) 0.0
𝑛 = number of studies.
Table 4: Pooled prevalences for hemorrhagic and ischemic stroke by selected risk factors for stroke.
Risk factor References Pooled prevalence -HS(% )
Pooled prevalence – IS
(% ) 𝑝
Hypertension 7 [15–17, 24–27] 73.5 62.8 0.001∗
Diabetes 7 [15–17, 24–27] 10.6 15.9 0.009∗
Alcohol use 4 [15, 16, 26, 27] 29.3 24.2 0.182
Smoking 6 [15, 16, 24–27] 11.2 13.1 0.340
Atrial fibrillation 5 [15, 16, 24, 25, 27] 2.3 9.6 0.001∗
HIV infection 2 [15, 16] 11.8 20.0 0.123
Hypercholesterolemia 4 [15, 16, 25, 27] 18.6 13.7 0.176
∗Statistical significance at 5% level.
for hemorrhagic and ischemic stroke separately, we per-
formed additional quantitative analyses using seven hospital-
based descriptive studies [15–17, 24–27]. These studies were
only reporting prevalences of risk factors for HS and IS
cases. We examined seven risk factors for HS and IS which
included hypertension, DM, AF, alcohol use, HIV infection,
smoking, and hypercholesterolemia. These were risk factors
with data available from more than one study. The overall
pooled prevalence of IS was 61.4% while HS was 33%. The
pooled prevalence of hypertension was higher for HS than
for IS (73.5% versus 62.8%), while DM and AF were more
prevalent among IS compared to HS (15.9% versus 10.6% and
9.6% versus 2.3%, respectively). The summary of the pooled
prevalences for HS and IS by selected risk factors for stroke is
summarized in Table 4.
4. Discussion
There remain too few data from SSA to reliably estimate the
effect of various factors on the risk of IS and HS. In this
review, we identified only five case-control studies from SSA
that reported information on risk factors for all stroke. Only
one study reported data on IS and HS risk factors separately.
Furthermore, the vast majority of cases were identified in
hospital and so are unlikely to be representative of the totality
of stroke cases in the community. Only 31 cases from Asiki
et al. and 200 from Walker et al. were community based
[12, 30]. Further work should include stroke cases identified
within the context of management of predominant stroke
risk factors such as diabetes and hypertension which can be
improved considering the optimal drug regimens available.
Interventions targeting accessibility to screening, treatment
and sociocultural aspects of health should be considered.
In line with previous research, this review showed that
DM is a risk factor for all stroke, but it is more prevalent
among those with IS than with HS. Data from previous
research has also demonstrated similar findings [8, 34–37].
The INTERSTROKE study was a landmark case-control
study, which confirmed that nine modifiable risk factors,
including DM, account for approximately 90% of the popu-
lation’s attributable risk for stroke in all regions of the world
including SSA [8]. Several other epidemiologic studies [38,
39] have indicated an independent association between DM
and IS with a twofold to sixfold increased risk. Diabetes is
major risk factor for the development of atherosclerosis and
the excess risk of stroke in patients with diabetes is about four
times higher when compared with normal individuals in a
general population [40]. Poorly controlled diabetes has been
shown to contribute to poor outcome in stroke patients [20].
Withmajority of the diabetic patients living in the developing
world, prevention and control of diabetes is becoming a
major public health priority [41]. World Health Organization
reports [42] have called for more resources to be spent on
vascular risk factor reduction in low-income countries and
for the development of new ways to provide preventive care.
Results from our study suggest that HIV is a risk factor
for all stroke, although it is more prevalent among those
with IS rather than HS. A similar finding was observed in a
study from Malawi [43]. In Tanzania, the overall prevalence
of HIV infection among patients presenting with stroke was
20.9% [44]. It is well recognized that both HIV infection
and antiretroviral therapy (ART) could potentially increase
an individual’s risk of stroke [45]. Given the epidemic of HIV
infection and the increasing burden of stroke in SSA, we need
large, well designed interventions to control the epidemic, to-
getherwith integration of care for noncommunicable diseases
(NCD) into HIV care programmes.
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In the limited data presented here, hypercholesterolemia,
smoking, alcohol use, male gender, and hypertension were
not significantly associated with stroke. The difference in the
pooled prevalences for HS and IS among patients with hyper-
tension, DM, and atrial AF was statistically significant at the
5% level. We did not have any information on the pack years
in the studies we analyzed. However, according to previous
research, the longer and heavier a person’s smoking habit, the
higher the risk of stroke [46]. The relationship between the
amount of smoking and stroke risk is strongest for ischemic
stroke [47]. Althoughwe did not find a significant association
between hypertension with all stroke, numerous studies [24,
26] have documented this relationship, and it is consistent
throughout SSA. Thus, hypertension is a key risk factor for
both HS and IS [9, 48]. Populations in SSA appear to be more
at-risk of developing hypertension and subsequent stroke
compared to the western world [8, 49]. This difference could
be accounted for by a combination of factors, including inad-
equate funding and lack of infrastructure which often impair
diagnosis, screening, treatment and control of hypertension
in SSA [9, 50].
5. Limitations
Our study has several potential limitations. We could not
report the comparative importance of risk factors for HS and
IS in SSA because of lack of published data. All included stud-
ies in this review were limited to English only from 1980 to
2016, so we may not have included all relevant studies despite
our comprehensive search strategy. Other limitations pertain
to the quality of the evidence provided by the included stud-
ies. Moderate to considerable heterogeneity existed among
the studies included in the outcome analysis and all but two of
the studies were hospital-based andmay not be representative
of the totality of stroke in the community. In Tanzania, only
a small proportion of stroke cases [12] get to hospital. This
highlights the biases associated with hospital-based studies
in SSA.
6. Conclusions and Recommendations
There remain too few data from SSA to reliably estimate the
effect of various factors on the risk of IS andHS. Furthermore,
the clear majority of cases were identified in hospital and so
are unlikely to be representative of the totality of stroke cases
in the community. Further work should include stroke cases
identified within the context of management of predominant
stroke risk factors such as diabetes and hypertension which
can be improved considering the optimal drug regimens
available. Interventions targeting accessibility to screening,
treatment, and sociocultural aspects of health should be con-
sidered.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Authors’ Contributions
Gertrude Namale conceived and designed the study; Ones-
mus Kamacooko performed the statistical analysis; Alison
Kinengyere andGertrudeNamale developed the search strat-
egy; Gertrude Namale wrote the manuscript; Patrick Cras,
Laetitia Yperzeele, EdwardDdumba, Janet Seeley, and Robert
Newton oversaw the overall execution of the manuscript
writing; Robert Newton oversaw the critical revisions of the
manuscript; all authors read and approved the final manu-
script.
Acknowledgments
The authors would like to thank the authors whom we
contacted for additional information, in particular those that
responded to our requests. Our sincere thanks also go to
Dr. Anthony Ekwaro Obuku from Africa Centre for System-
atic Reviews and Knowledge Translation, College of Health
Sciences, Makerere University, Kampala, Uganda, and Dr.
John Bosco M Ddamulira from the School of Public Health,
College of Health Sciences, Makerere University, Kampala,
Uganda, who provided insight and comments that greatly
improved the manuscript. They would like to acknowledge
the University of Antwerp andUKMedical Research Council
(MRC) and the UK Department for International Develop-
ment (DFID) under the MRC/DFID Concordat agreement
which is also part of the EDCTP2 programme supported by
the European Union for the funding.
References
[1] C. Mathers, D. M. Fat, and J. T. Boerma, The global burden of
disease: 2004 update, World Health Organization, 2008.
[2] WHO, WHO STEPS Stroke Manual: The WHO STEPwise Ap-
proach to Stroke Surveillance, WHO, 2005.
[3] T. Truelsen, R. Bonita, and K. Jamrozik, “Surveillance of stroke:
A global perspective,” International Journal of Epidemiology, vol.
30, pp. S11–S16, 2001.
[4] R. Bonita, S. Mendis, T. Truelsen, J. Bogousslavsky, J. Toole, and
F. Yatsu, “The global stroke initiative,”TheLancet Neurology, vol.
3, no. 7, pp. 391–393, 2004.
[5] M. S. Elkind and R. L. Sacco, “Stroke risk factors and stroke pre-
vention,” Seminars in Neurology, vol. 18, no. 4, pp. 429–440,
1998.
[6] WHO, “STEPS-Stroke Manual,” 2007.
[7] M. D. Connor, M.Thorogood, G. Modi, and C. P. Warlow, “The
Burden of Stroke in Sub-Saharan Africa,” American Journal of
Preventive Medicine, vol. 33, no. 2, pp. 172-173, 2007.
[8] M. J. O’Donnell, X. Denis, L. Liu et al., “Risk factors for ischae-
mic and intracerebral haemorrhagic stroke in 22 countries (the
INTERSTROKE study): a case-control study,” The Lancet, vol.
376, no. 9735, pp. 112–123, 2010.
[9] D. Lemogoum, J.-P. Degaute, and P. Bovet, “Stroke prevention,
treatment, and rehabilitation in Sub-Saharan Africa,” American
Journal of Preventive Medicine, vol. 29, no. 5, supplement 1, pp.
95–101, 2005.
[10] R. L. Sacco, B. Boden-Albala, G. Abel et al., “Race-ethnic dis-
parities in the impact of stroke risk factors the Northern Man-
hattan stroke study,” Stroke, vol. 32, no. 8, pp. 1725–1731, 2001.
[11] Y. K. Seedat, “Hypertension in developing nations in sub-
Saharan Africa,” Journal of Human Hypertension, vol. 14, no. 10-
11, pp. 739–747, 2000.
10 Journal of Tropical Medicine
[12] R.W.Walker, A. Jusabani, E. Aris et al., “Stroke risk factors in an
incident population in urban and rural Tanzania: A prospec-
tive, community-based, case-control study,” The Lancet Global
Health, vol. 1, no. 5, pp. e282–e288, 2013.
[13] J. Nakibuuka, N. Abwooli, A. Namale, N. A. Blondin, and E.
Ddumba, “A descriptive epidemiological study on stroke in
Kampala, Uganda: A hospital-based study,” African Journal of
Neurological Sciences, vol. 31, no. 1, 2012.
[14] J. Nakibuuka, M. Sajatovic, J. Nankabirwa et al., “Stroke-risk
factors differ between rural and urban communities: Population
survey in central uganda,”Neuroepidemiology, vol. 44, no. 3, pp.
156–165, 2015.
[15] N. Jane et al., “A descriptive epidemiological study on stroke
in Kampala, Uganda: a hospital-based study,” African Journal of
Neurological Sciences, vol. 31, pp. 41–48, 2012.
[16] M. Atadzhanov, “Stroke characteristics and outcomes of adult
patients admitted to the university teaching hospital, Lusaka,
Zambia,”The Open General and Internal Medicine Journal, vol.
5, no. 1, pp. 3–8, 2012.
[17] S. A. Gebremariam and H. S. Yang, “Types, risk profiles, and
outcomes of stroke patients in a tertiary teaching hospital in
northern Ethiopia,” eNeurologicalSci, vol. 3, pp. 41–47, 2016.
[18] J. Matenga, “Stroke incidence rates among black residents of
Harare - A prospective community-based study,” South African
Medical Journal, vol. 87, no. 5, pp. 606–609, 1997.
[19] G. Zenebe, M. Alemayehu, and J. Asmera, “Characteristics and
outcomes of stroke at Tikur Anbessa Teaching Hospital, Ethio-
pia,” EthiopianMedical Journal, vol. 43, no. 4, pp. 251–259, 2005.
[20] J. O. Jowi and P.M.Mativo, “Pathological sub-types, risk factors
and outcome of stroke at the Nairobi hospital, Kenya,” East
African Medical Journal, vol. 85, no. 12, pp. 572–581, 2008.
[21] B.Ogungbo,D.Okor, and F. I. Ojini, “Management of ischaemic
stroke: The role of the neurosurgeon,” West African Journal of
Medicine, vol. 29, no. 3, pp. 143–145, 2010.
[22] D. R. Lisk, “Stroke risk factors in an african population: a report
from sierra leone,” Stroke, vol. 24, no. 1, pp. 139-140, 1993.
[23] D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred
reporting items for systematic reviews and meta-analyses: the
PRISMA statement,” PLoS Medicine, vol. 6, no. 7, Article ID
e1000097, 2009.
[24] A.Damasceno, J. Gomes, A. Azevedo et al., “An epidemiological
study of stroke hospitalizations in maputo, mozambique: a high
burden of disease in a resource-poor country,” Stroke, vol. 41,
no. 11, pp. 2463–2469, 2010.
[25] E. Sagui, P. S. M’Baye, C. Dubecq et al., “Ischemic and hem-
orrhagic strokes in Dakar, Senegal: A hospital-based study,”
Stroke, vol. 36, no. 9, pp. 1844–1847, 2005.
[26] M. O. Owolabi and A. M. Agunloye, “Which risk factors are
more associated with ischemic rather than hemorrhagic stroke
in black Africans?” Clinical Neurology and Neurosurgery, vol.
115, no. 10, pp. 2069–2074, 2013.
[27] M. D. Connor, A Racial And Urban-Rural Comparison of the
Nature of Stroke in South Africa, Faculty of Health Sciences,
University of the Witwatersrand, 2007.
[28] G.Wells et al., “NewCastle–Ottawa Quality Assessment Scale—
Case Control Studies,” 2012.
[29] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman,
“Measuring inconsistency in meta-analyses,” British Medical
Journal, vol. 327, no. 7414, pp. 557–560, 2003.
[30] G. Asiki, L. Stockdale, I. Kasamba et al., “Pilot study of antibod-
ies against varicella zoster virus and human immunodeficiency
virus in relation to the risk of developing stroke, nested within
a rural cohort in Uganda,” Tropical Medicine & International
Health, vol. 20, no. 10, pp. 1306–1310, 2015.
[31] M. O. Owolabi and A. M. Agunloye, “Risk factors for stroke
among patients with hypertension: A case-control study,” Jour-
nal of the Neurological Sciences, vol. 325, no. 1-2, pp. 51–56, 2013.
[32] L. A. Benjamin, E. L. Corbett, M. D. Connor et al., “HIV, anti-
retroviral treatment, hypertension, and stroke in Malawian
adults,” Neurology, vol. 86, no. 4, pp. 324–333, 2016.
[33] J. C. Valentine, T. D. Pigott, and H. R. Rothstein, “How many
studies do you need? A primer on statistical power for meta-
analysis,” Journal of Educational andBehavioral Statistics (JEBS),
vol. 35, no. 2, pp. 215–247, 2010.
[34] G. Hu, C. Sarti, P. Jousilahti et al., “The impact of history of hy-
pertension and type 2 diabetes at baseline on the incidence of
stroke and stroke mortality,” Stroke, vol. 36, no. 12, pp. 2538–
2543, 2005.
[35] G. Hu, P. Jousilahti, C. Sarti, R. Antikainen, and J. Tuomilehto,
“The effect of diabetes and stroke at baseline and during follow-
up on stroke mortality,” Diabetologia, vol. 49, no. 10, pp. 2309–
2316, 2006.
[36] C. M. Burchfiel, J. David Curb, B. L. Rodriguez, R. D. Abbott,
D. Chiu, and K. Yano, “Glucose intolerance and 22-year stroke
incidence: the honolulu heart program,” Stroke, vol. 25, no. 5,
pp. 951–957, 1994.
[37] H. S. Jørgensen, H. Nakayama, H. O. Raaschou, and T. S. Olsen,
“Stroke in patients with diabetes: the Copenhagen stroke study,”
Stroke, vol. 25, no. 10, pp. 1977–1984, 1994.
[38] W.Matuja,M. Janabi, R. Kazema, andD.Mashuke, “Stroke Sub-
types in Black Tanzanians: A Retrospective Study of Com-
puterized Tomography Scan Diagnoses at Muhimbili National
Hospital, Dar es,” Tropical Doctor, vol. 34, no. 3, pp. 144–146,
2004.
[39] A. I. Qureshi, K. Safdar, M. Patel, R. S. Janssen, and M. R. Fran-
kel, “Stroke in young black patients: Risk factors, subtypes, and
prognosis,” Stroke, vol. 26, no. 11, pp. 1995–1998, 1995.
[40] S. R. Hasan and A. S. K. Ghouri, “Frequency of known risk fac-
tors of stroke and its outcome in patients admitted in Sindh
Government Qatar Hospital Karachi,” Pakistan Journal of Med-
ical Sciences, vol. 23, no. 4, pp. 634–636, 2007.
[41] H. King, R. E. Aubert, and W. H. Herman, “Global burden
of diabetes, 1995–2025: prevalence, numerical estimates, and
projections,” Diabetes Care, vol. 21, no. 9, pp. 1414–1431, 1998.
[42] J.-J. Guilbert, “The world health report 2002—reducing risks,
promoting healthy life,” Education for Health, vol. 16, no. 2,
article 230, 2003.
[43] T. Heikinheimo, D. Chimbayo, J. J. Kumwenda, S. Kampondeni,
and T. J. Allain, “Stroke outcomes in Malawi, a country with
high prevalence of HIV: A prospective follow-up study,” PLoS
ONE, vol. 7, no. 3, Article ID e33765, 2012.
[44] M.Mlay andM. Bakari, “The prevalence ofHIV among patients
admittedwith stroke at theMuhimbili NationalHospital, Dar es
Salaam, Tanzania,” Tanzania Journal of Health Research, vol. 12,
no. 2, pp. 105–113, 2010.
[45] S. Sen, A. A. Rabinstein, M. S. Elkind, and W. J. Powers, “Re-
cent developments regarding human immunodeficiency virus
infection and stroke,” Cerebrovascular Disease, vol. 33, no. 3, pp.
209–218, 2012.
[46] G. S. Tell, J. F. Polak, B. J. Ward, S. J. Kittner, P. J. Savage, and
J. Robbins, “Relation of smoking with carotid artery wall thick-
ness and stenosis in older adults: The Cardiovascular Health
Study,” Circulation, vol. 90, no. 6, pp. 2905–2908, 1994.
Journal of Tropical Medicine 11
[47] P. Smith, “Smoking and stroke: a causative role,” British Medical
Journal, vol. 317, pp. 962-963, 1998.
[48] R. V. Krishnamurthi, V. L. Feigin, M. H. Forouzanfar et al.,
“Global and regional burden of first-ever ischaemic and haem-
orrhagic stroke during 1990–2010: findings from the Global
Burden of Disease Study 2010,” The Lancet Global Health, vol.
1, no. 5, pp. e259–e281, 2013.
[49] T. Richard, “Stroke in SSA: review of current literature concern-
ing the incidence, risk factors and mortality in this demo-
graphic,” Hypertension, vol. 73, p. 71, 2013.
[50] R. W. Walker, D. G. McLarty, H. M. Kitange et al., “Stroke mor-
tality in urban and rural Tanzania,” The Lancet, vol. 355, no.
9216, pp. 1684–1687, 2000.
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
